Compare 8x8 Inc (EGHT) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
8x8 Inc vs State Street SPDR S&P Biotech ETF — how do they compare? 8x8 Inc trades at $2.03 (market cap $279.31M), while State Street SPDR S&P Biotech ETF trades at $151.81. The key difference: State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, 8x8 Inc nearer its low. Which is the better fit depends on your goals.
| EGHT | XBI | |
|---|---|---|
Market Cap | $279.31M | — |
Sector | Technology | Broad Market / Factor |
52-Week High | $2.76 | $164.28 |
52-Week Low | $1.59 | $85.16 |
Enterprise Value | $556.99M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EGHT (8x8, Inc.) trades at $2.035, down 6.22% on the day. The stock shows a bullish technical signal from moving averages, though oscillators are neutral. Fundamentally, the company reported a net loss of $27.21M for 2025 but has beaten EPS estimates for three consecutive quarters. Recent news highlights product innovation with AI Routing and Pulse solutions, and the company was named a 2026 MetriStar Top Provider for CPaaS. Revenue grew to $715.07M in 2025, with a forecasted return to profitability in 2026.
The outlook hinges on the company's transition to profitability, projected for 2026 with a net profit of $2M. Investment opportunities include continued revenue growth, successful execution of new AI-driven products, and cost discipline. Key risks are the high P/E ratio of 197, significant long-term debt of $338.37M, and the challenge of sustaining recent earnings beats. Analyst sentiment is mixed but leans positive, with 39% Buy ratings.
XBI (SPDR S&P Biotech ETF) trades at $152.07, down 2.23% today, but maintains a bullish technical outlook with strong momentum indicators. The ETF has gained significant attention with a 17% monthly surge, driven by biotech sector strength and increased M&A activity. Analyst coverage shows a cautious stance with 100% hold rating, reflecting balanced risk-reward assessment amid sector volatility.
The biotech sector shows strong momentum with AI drug discovery advances and record M&A activity ($106 billion in 2026). While XBI offers high-beta exposure to small/mid-cap biotech growth, investors face elevated volatility and regulatory uncertainties. The equal-weight portfolio structure provides diversified exposure to sector innovation but requires tolerance for price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 8x8 Inc
8x8 is a provider of integrated cloud communications and contact center solutions. Its platform combines voice, video, chat, and contact center functionality into a single application to help businesses collaborate.
Read more on EGHT →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
